Quadruple and Phytomedicine-based Therapies in H. Pylori Infection
NCT ID: NCT02004197
Last Updated: 2013-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
176 participants
INTERVENTIONAL
2010-01-31
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pylorex plus
Pylorex plus consisting of medicinal plants.
Quadruple Allopathic therapy
Pylorex plus
Quadruple therapy
Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
Quadruple Allopathic therapy
Pylorex plus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quadruple Allopathic therapy
Pylorex plus
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients having no previous record of treatment against H. pylori infection
3. Patients living in Karachi, Rawalpindi and Bahawalpur
4. Patients having no pathological complications on routine examination
5. All socioeconomic classes were included in the study
6. Male and female patients between 15 to 45 years of age
Exclusion Criteria
2. if history of use of antibiotics, proton-pump inhibitors or bismuth compound in the last one month before test
3. any patient found to be allergic or intolerant to therapeutic regimens
4. they failed to report for follow-up
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hafiz Muhammad Asif
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hafiz Muhammad Asif
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khan Usman Ghani, Ph. D
Role: STUDY_DIRECTOR
Hamdard University Karachi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
clinical trial was conducted in high risk areas of Pakistan such as Karachi, Bahawalpur, Islamabad and Rawalpindi at Shifa-Ul-Mulk Memorial Hospital, Hamdrad University Karachi, Bahawalpur Victoria Hospital and Nawaz Salik Hospital respectively
Karachi, , Pakistan
Shifa Ul MUlk Memorial Hospital
Karachi, , Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Asif-HP-001
Identifier Type: -
Identifier Source: org_study_id